Cue Biopharma
100 hedge funds and large institutions have $393M invested in Cue Biopharma in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
35% more funds holding
Funds holding: 74 → 100 (+26)
7.19% more ownership
Funds ownership: 49.2% → 56.39% (+7.2%)
15% less call options, than puts
Call options by funds: $1.29M | Put options by funds: $1.53M
Holders
100
Holding in Top 10
3
Calls
$1.29M
Puts
$1.53M
Top Buyers
| 1 | +$16.2M | |
| 2 | +$16.1M | |
| 3 | +$14.8M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.22M |
Top Sellers
| 1 | -$8.53M | |
| 2 | -$5.93M | |
| 3 | -$4.37M | |
| 4 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$3.92M |
| 5 |
CAG
Crestwood Advisors Group
Boston,
Massachusetts
|
-$3.83M |